These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 26558256)
21. Local (topical and intraocular) therapy for ocular Adamantiades-Behçet's disease. Fabiani C; Alió JL Curr Opin Ophthalmol; 2015 Nov; 26(6):546-52. PubMed ID: 26367091 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of corticosteroids and cyclosporin in the treatment of retinal vasculitis in patients with Behçet's disease. Ermakova NA Adv Exp Med Biol; 2003; 528():563-5. PubMed ID: 12918765 [No Abstract] [Full Text] [Related]
23. [Prognostic factors of ocular involvement in Behçet's disease]. Belkhadir K; Boutimzine N; Laghmari M; Amazouzi A; Tachfouti S; Cherkaoui O J Fr Ophtalmol; 2019 Jun; 42(6):612-617. PubMed ID: 31088739 [TBL] [Abstract][Full Text] [Related]
24. Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behcet's disease: longitudinal study of up to 10 years. Davatchi F; Sadeghi Abdollahi B; Shams H; Shahram F; Nadji A; Chams-Davatchi C; Faezi T; Akhlaghi M; Ghodsi Z; Ashofteh F; Mohtasham N Int J Rheum Dis; 2014 May; 17(4):444-52. PubMed ID: 24314325 [TBL] [Abstract][Full Text] [Related]
27. [Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a]. Deuter CM; Kötter I; Günaydin I; Zierhut M; Stübiger N Ophthalmologe; 2004 Feb; 101(2):129-34. PubMed ID: 14991308 [TBL] [Abstract][Full Text] [Related]
33. Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet's disease. Krause L; Turnbull JR; Torun N; Pleyer U; Zouboulis CC; Foerster MH Adv Exp Med Biol; 2003; 528():511-9. PubMed ID: 12918754 [No Abstract] [Full Text] [Related]
34. Evaluation of current therapeutic strategies in Behçet's disease. Alexoudi I; Kapsimali V; Vaiopoulos A; Kanakis M; Vaiopoulos G Clin Rheumatol; 2011 Feb; 30(2):157-63. PubMed ID: 20842513 [TBL] [Abstract][Full Text] [Related]
35. Advances in pathogenesis and treatment of ocular involvement in Behcet's disease. Lin S; Xu Z; Lin Z; Xie B; Feng J Front Immunol; 2023; 14():1206959. PubMed ID: 37841268 [TBL] [Abstract][Full Text] [Related]
36. Pattern and causes of visual loss in Behçet's uveitis: short-term and long-term outcomes. Amer R; Alsughayyar W; Almeida D Graefes Arch Clin Exp Ophthalmol; 2017 Jul; 255(7):1423-1432. PubMed ID: 28396946 [TBL] [Abstract][Full Text] [Related]
37. Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet's disease. Adler YD; Mansmann U; Zouboulis CC Dermatology; 2001; 203(4):322-4. PubMed ID: 11752821 [TBL] [Abstract][Full Text] [Related]
38. Current and future treatments for Behçet's uveitis: road to remission. Mesquida M; Molins B; Llorenç V; Hernández MV; Espinosa G; Dick AD; Adán A Int Ophthalmol; 2014 Apr; 34(2):365-81. PubMed ID: 23729309 [TBL] [Abstract][Full Text] [Related]
39. Multifocal ERG changes in patients with ocular Behçet's disease during therapy with interferon alpha 2a. Stübiger N; Besch D; Deuter CM; Zierhut M; Kötter I Adv Exp Med Biol; 2003; 528():529-32. PubMed ID: 12918757 [No Abstract] [Full Text] [Related]
40. [Clinical features of patients with Behcet's uveitis]. Liu XS; Gao F; Zhao C; Zhang MF Zhonghua Yan Ke Za Zhi; 2020 Mar; 56(3):217-223. PubMed ID: 32187951 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]